SEC Tracker
Get the app

Biomea Fusion BMEA

Biomea Fusion reports Q3 2026 financial results and clinical updates

Biomea Fusion (BMEA) filed an 8-K with the SEC on Nov 10, 2026, 4:28 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Completed enrollment in COVALENT-211 trial for icovamenib in insulin-deficient T2D
  2. Topline data for COVALENT-211 expected Q1 2027
  3. BMF-650 showed 6.1% weight reduction in Phase I trial
  4. Cash runway projected into Q2 2027

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Biomea Fusion files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.